Cryptococcal Meningitis
文献摘要
Cryptococcal meningitis is a life-threatening fungal infection of the central nervous system (CNS) caused primarily by Cryptococcus neoformans and Cryptococcus gattii. It represents one of the most important causes of subacute and chronic meningitis worldwide and remains a major driver of infectious mortality, particularly among individuals with advanced HIV infection. Despite substantial advances in antiretroviral therapy, antifungal regimens, and diagnostic testing, cryptococcal meningitis continues to account for a significant proportion of AIDS-related deaths globally, with the highest burden concentrated in regions where late HIV presentation and limited access to optimal induction therapy and intracranial pressure (ICP) monitoring persist. Human infection is typically acquired through inhalation of environmental propagules, followed by pulmonary establishment and, in susceptible hosts, hematogenous dissemination to the CNS. Although advanced HIV disease, especially with CD4 counts below 100 cells/mm³, is the most important global risk factor, cryptococcal meningitis also occurs in solid organ transplant recipients, patients receiving prolonged glucocorticoids or other immunosuppressive therapies, individuals with hematologic malignancies or immune-dysregulating conditions, and, less commonly, in apparently immunocompetent hosts. Disease phenotype and inflammatory response vary considerably across these groups, influencing presentation, diagnostic findings, treatment duration, and risk of complications. Clinically, cryptococcal meningitis most often presents as subacute meningoencephalitis, characterized by progressive headache, fever, and cognitive or behavioral changes that evolve over days to weeks. Classic meningeal signs may be absent, particularly in profoundly immunosuppressed patients, and focal neurologic deficits or visual symptoms may reflect elevated ICP, hydrocephalus, or focal mass lesions such as cryptococcomas. Because symptoms can be nonspecific and indolent, delayed diagnosis remains common and is strongly associated with poor outcomes. Modern management rests on the following 3 core principles: 1. Rapid confirmation of diagnosis, most commonly through cerebrospinal fluid (CSF) cryptococcal antigen testing and culture. 2. Immediate initiation of phase-based antifungal therapy (induction, consolidation, and maintenance) tailored to host category and resource setting. 3. Aggressive recognition and control of elevated ICP, which is a major, modifiable determinant of early mortality. In HIV-associated disease, careful timing of antiretroviral therapy is additionally required to reduce the risk of immune reconstitution inflammatory syndrome (IRIS), while in transplant and other immunosuppressed populations, thoughtful coordination of immunosuppression adjustments is essential. Even with appropriate therapy, mortality remains substantial, and survivors frequently experience long-term neurologic and functional impairment. Outcomes are shaped not only by fungal burden and host immune status, but also by health-system factors, eg, timely access to flucytosine-containing induction regimens, the ability to measure and manage ICP, and structured follow-up during prolonged suppressive therapy. A comprehensive, clinically oriented framework is essential for understanding the pathophysiology, presentation, diagnostic approach, treatment strategies, complications, prognosis, and interprofessional management of cryptococcal meningitis, with particular emphasis on decision points that influence survival, including early diagnosis, culture-informed reassessment, and ICP-directed supportive care.